Drug Trial Radar · NCT06775834
Safety and Pharmacokinetics Study of HRS-1893 Tablets in Healthy Subjects and Those With Impaired Kidney Function
Last checked: Nov 20, 2026Latest source record: Sep 10, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
24
Actual
Start
Feb 11, 2025
Primary completion
Jul 23, 2025
Study completion Jul 23, 2025
Sponsor
- Lead sponsor
- Shandong Suncadia Medicine Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jan 15, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The primary objective is to evaluate pharmacokinetics of HRS-1893 tablets in subjects with impaired kidney function in comparison with healthy subjects, to develop dose recommendations for patients with renal impairment.
Conditions
- Hypertrophic Cardiomyopathy
Interventions
HRS-1893Drug
HRS-1893 tablets.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum plasma concentration (Cmax)Time frame: 0 hour to 16 days after the dosing.
- Area under the plasma concentration-time curve from time zero to the time of last quantifiable analyte concentration (AUC0-t)Time frame: 0 hour to 16 days after the dosing.
- Area under the plasma concentration-time curve from time zero extrapolated to infinity (AUC0-∞)Time frame: 0 hour to 16 days after the dosing.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Sichuan Provincial People's Hospital
Chengdu, Sichuan, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.